GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (LTS:0MTD) » Definitions » EV-to-Revenue

Swedish Orphan Biovitrum AB (LTS:0MTD) EV-to-Revenue : 4.94 (As of Dec. 15, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Swedish Orphan Biovitrum AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Swedish Orphan Biovitrum AB's enterprise value is kr125,526 Mil. Swedish Orphan Biovitrum AB's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was kr25,435 Mil. Therefore, Swedish Orphan Biovitrum AB's EV-to-Revenue for today is 4.94.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's EV-to-Revenue or its related term are showing as below:

LTS:0MTD' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.63   Med: 5.17   Max: 12.84
Current: 4.94

During the past 13 years, the highest EV-to-Revenue of Swedish Orphan Biovitrum AB was 12.84. The lowest was 3.63. And the median was 5.17.

LTS:0MTD's EV-to-Revenue is ranked worse than
73.14% of 994 companies
in the Drug Manufacturers industry
Industry Median: 2.495 vs LTS:0MTD: 4.94

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-12-15), Swedish Orphan Biovitrum AB's stock price is kr314.70. Swedish Orphan Biovitrum AB's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was kr72.93. Therefore, Swedish Orphan Biovitrum AB's PS Ratio for today is 4.31.


Swedish Orphan Biovitrum AB EV-to-Revenue Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB EV-to-Revenue Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.30 4.14 4.15 3.81 4.99

Swedish Orphan Biovitrum AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.52 4.99 4.73 4.79 5.10

Competitive Comparison of Swedish Orphan Biovitrum AB's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's EV-to-Revenue falls into.



Swedish Orphan Biovitrum AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Swedish Orphan Biovitrum AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=125525.552/25435
=4.94

Swedish Orphan Biovitrum AB's current Enterprise Value is kr125,526 Mil.
Swedish Orphan Biovitrum AB's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr25,435 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Swedish Orphan Biovitrum AB  (LTS:0MTD) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Swedish Orphan Biovitrum AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=314.70/72.933
=4.31

Swedish Orphan Biovitrum AB's share price for today is kr314.70.
Swedish Orphan Biovitrum AB's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr72.93.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Swedish Orphan Biovitrum AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB Business Description

Traded in Other Exchanges
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB Headlines

No Headlines